Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for Thomas R. Sheehy
-0.02 (-0.56%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.47 - 3.58
52 week 1.34 - 4.10
Open 3.58
Vol / Avg. 71,010.00/119,782.00
Mkt cap 140.40M
P/E     -
Div/yield     -
EPS -0.76
Shares 39.55M
Beta 1.23
Inst. own 41%
Mar 10, 2015
Codexis Inc at ROTH Conference - 11:00AM EDT - Add to calendar
Mar 3, 2015
Q4 2014 Codexis Inc Earnings Call - 4:30PM EST - Add to calendar
Mar 3, 2015
Q4 2014 Codexis Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 9, 2015
Codexis Inc at Biotechnology Industry Organization CEO & Investor Conference
Dec 4, 2014
Codexis Inc at LD Micro Conference
Dec 4, 2014
Codexis, Inc. at the LD Micro Main Event VII Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -61.05% -129.39%
Operating margin -56.95% -128.90%
EBITD margin - -94.12%
Return on average assets -40.65% -52.02%
Return on average equity -67.11% -68.88%
Employees 125 -
CDP Score - -


200 Penobscot Drive
United States - Map
+1-650-4218100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Codexis, Inc. is a developer of biocatalysts. The Company is engaged in the pharmaceutical and fine chemical industries. The Company�s technology platform enables the evolution and optimization of biocatalysts to perform specific chemical reactions. The pharmaceutical customers use its technology, products and services in their manufacturing process development and production of drugs. The technology helps to develop biocatalysts for use in the fine chemicals markets, such as food, animal feed, polymers, flavors and fragrances and agricultural chemicals. The Company�s technologies enable scale-up and implementation of biocatalytic solutions for sustainable process development, from research to manufacturing. The Company�s products apply CodeEvolver directed evolution technology platform, which introduce genetic mutations into microorganisms, giving rise to changes in the enzymes.

Officers and directors

Thomas R. Baruch Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Gordon T. Sangster Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Pam P. Cheng Director
Bio & Compensation  - Reuters
Kathleen Sereda Glaub Director
Age: 51
Bio & Compensation  - Reuters
Patrick Y. Yang Ph.D. Director
Age: 66
Bio & Compensation  - Reuters
Byron L. Dorgan Independent Director
Age: 71
Bio & Compensation  - Reuters
Alexander A. Karsner Independent Director
Age: 46
Bio & Compensation  - Reuters